Currently, there is no effective cure for the metastatic castration resistant prostate cancer. We investigate CCM regulation of YAP/TAZ signaling, responsible both for the castration resistance and also metastatic hallmarks in prostate cancer. Importantly, we found that CCM expression is uniquely increased in advanced stage of prostate cancer and inversely correlates with metastasis free survival and overall survival of human prostate cancer patients. CCM is becoming a central regulator of prostate cancer progression, providing a new rationale for therapeutic CCM targeting in prostate cancer patients. 

Additionally, vascular integrity is important for the control of sepsis and metastasis. In our lab, various small molecules are investigated with regard to their effects on vascular functions.